NASDAQ:IPA ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free IPA Stock Alerts $1.26 +0.04 (+3.28%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$1.26▼$1.2650-Day Range$1.22▼$1.9852-Week Range$0.94▼$4.22Volume305 shsAverage Volume494,850 shsMarket Capitalization$33.16 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get ImmunoPrecise Antibodies alerts: Email Address ImmunoPrecise Antibodies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside473.8% Upside$7.00 Price TargetShort InterestHealthy1.48% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.36) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.75 out of 5 starsMedical Sector411th out of 909 stocksPharmaceutical Preparations Industry183rd out of 425 stocks 3.5 Analyst's Opinion Consensus RatingImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunoPrecise Antibodies has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.48% of the float of ImmunoPrecise Antibodies has been sold short.Short Interest Ratio / Days to CoverImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoPrecise Antibodies has recently decreased by 27.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunoPrecise Antibodies does not currently pay a dividend.Dividend GrowthImmunoPrecise Antibodies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPA. Previous Next N/A News and Social Media Coverage Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.Percentage Held by InstitutionsOnly 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.36) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoPrecise Antibodies is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoPrecise Antibodies is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoPrecise Antibodies has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Read More IPA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPA Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare ApplicationsMarch 28, 2024 | businesswire.comInterSystems and IPA's Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare ApplicationsApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 20, 2024 | businesswire.comIPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI DevelopmentsMarch 15, 2024 | msn.comImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2024 Earnings Call TranscriptMarch 14, 2024 | investorplace.comIPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024March 7, 2024 | finance.yahoo.comIPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT TechnologyMarch 7, 2024 | businesswire.comIPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT TechnologyApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 4, 2024 | finance.yahoo.comIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024December 16, 2023 | markets.businessinsider.comBuy Rating on ImmunoPrecise Antibodies Reflects Strong Revenue Growth and Cost Management SuccessDecember 8, 2023 | finance.yahoo.comIPA Announces Closing of $1.265 Million Public Offering of Common SharesDecember 6, 2023 | benzinga.comWhy ImmunoPrecise Antibodies (IPA) Stock Is Down 20% TodayDecember 6, 2023 | investorplace.comWhy Is ImmunoPrecise Antibodies (IPA) Stock Down 39% Today?December 6, 2023 | finance.yahoo.comIPA Announces Pricing of $1.1 Million Public Offering of Common SharesDecember 5, 2023 | investing.comAfter-hours movers: SentinelOne up on earnings, MongoDB sees 'sell the news' reactionDecember 5, 2023 | finance.yahoo.comIPA Announces Proposed Public Offering of Common SharesNovember 27, 2023 | businesswire.comImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release CallNovember 22, 2023 | finance.yahoo.comImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug DiscoveryNovember 20, 2023 | benzinga.comImmunoPrecise's BioStrand® Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug DiscoveryOctober 25, 2023 | stockhouse.comIPA's Subsidiary, BioStrand, Provides an Update on LENSai(TM)October 25, 2023 | benzinga.comIPA's Subsidiary, BioStrand, Provides an Update on LENSai™October 25, 2023 | financialpost.comIPA’s Subsidiary, BioStrand, Provides an Update on LENSai™October 20, 2023 | finance.yahoo.comOvercoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological DataOctober 20, 2023 | finance.yahoo.comHow ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody ResearchSeptember 19, 2023 | finance.yahoo.comImmunoPrecise Antibodies Announces CFO TransitionSeptember 18, 2023 | nasdaq.comHC Wainwright & Co. Reiterates ImmunoPrecise Antibodies (IPA) Buy RecommendationSee More Headlines Receive IPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/24/2024Fiscal Year End4/30/2024Next Earnings (Estimated)7/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IPA CUSIPN/A CIK1715925 Webwww.immunoprecise.com Phone250-483-0308FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+455.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,980,000.00 Net Margins-60.23% Pretax Margin-66.12% Return on Equity-26.54% Return on Assets-18.36% Debt Debt-to-Equity Ratio0.25 Current Ratio1.66 Quick Ratio1.38 Sales & Book Value Annual Sales$15.61 million Price / Sales2.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.74 per share Price / Book0.72Miscellaneous Outstanding Shares26,320,000Free Float24,518,000Market Cap$33.16 million OptionableNot Optionable Beta0.09 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Jennifer Lynne Bath Ph.D.CEO, President & Non-Independent DirectorDr. Ilse RoodinkChief Scientific Officer & Interim General Manager of IPA Europe, OssMs. Kristin Taylor CPAM.B.A., Chief Financial OfficerMr. David E. OrtonChief Operating OfficerDr. Roland RomijnHead of General Operations of the Utrecht site of IPA (Europe)Key CompetitorsAcurx PharmaceuticalsNASDAQ:ACXPTheratechnologiesNASDAQ:THTXCASI PharmaceuticalsNASDAQ:CASIVYNE TherapeuticsNASDAQ:VYNEViracta TherapeuticsNASDAQ:VIRXView All CompetitorsInstitutional OwnershipSimplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%Ingalls & Snyder LLCBought 253,052 shares on 1/29/2024Ownership: 4.868%View All Institutional Transactions IPA Stock Analysis - Frequently Asked Questions Should I buy or sell ImmunoPrecise Antibodies stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPA shares. View IPA analyst ratings or view top-rated stocks. What is ImmunoPrecise Antibodies' stock price target for 2024? 2 brokerages have issued 1 year price objectives for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $5.00 to $9.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 473.8% from the stock's current price. View analysts price targets for IPA or view top-rated stocks among Wall Street analysts. How have IPA shares performed in 2024? ImmunoPrecise Antibodies' stock was trading at $1.71 at the beginning of 2024. Since then, IPA shares have decreased by 28.7% and is now trading at $1.22. View the best growth stocks for 2024 here. Are investors shorting ImmunoPrecise Antibodies? ImmunoPrecise Antibodies saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 318,200 shares, a drop of 27.8% from the March 15th total of 440,700 shares. Based on an average daily trading volume, of 578,700 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.5% of the shares of the company are sold short. View ImmunoPrecise Antibodies' Short Interest. When is ImmunoPrecise Antibodies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 8th 2024. View our IPA earnings forecast. How were ImmunoPrecise Antibodies' earnings last quarter? ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) announced its quarterly earnings results on Thursday, March, 14th. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). The business had revenue of $4.60 million for the quarter, compared to analysts' expectations of $4.43 million. ImmunoPrecise Antibodies had a negative net margin of 60.23% and a negative trailing twelve-month return on equity of 26.54%. How do I buy shares of ImmunoPrecise Antibodies? Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IPA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingElon Musk’s Controversial New Project: “Apollo”InvestorPlaceBiden out June 13; Kamala won’t replace him?Paradigm PressNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
